What is Clinuvel Pharmaceuticals Enterprise Value?
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Clinuvel Pharmaceuticals's Enterprise Value is $375.53 Mil.
Clinuvel Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $33.35 Mil. Therefore, Clinuvel Pharmaceuticals's EV-to-EBIT ratio for today is 11.26.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Clinuvel Pharmaceuticals's Enterprise Value
For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinuvel Pharmaceuticals's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Clinuvel Pharmaceuticals's Enterprise Value falls into.
Clinuvel Pharmaceuticals Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Clinuvel Pharmaceuticals's Enterprise Value for the fiscal year that ended in Jun. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinuvel Pharmaceuticals (OTCPK:CLVLF) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Clinuvel Pharmaceuticals's EV-to-EBIT for today is
Clinuvel Pharmaceuticals's current Enterprise Value is $375.53 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Clinuvel Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $33.35 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Clinuvel Pharmaceuticals's EV-to-EBITDA for today is:
Clinuvel Pharmaceuticals's current Enterprise Value is $375.53 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Clinuvel Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $34.01 Mil.
Clinuvel Pharmaceuticals's current Enterprise Value is $375.53 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Clinuvel Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $54.45 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinuvel Pharmaceuticals Enterprise Value Related Terms
Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Business Description
Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CLVLF has been successfully added to your 